Shares of Icon Plc (NASDAQ:ICLR – Get Free Report) have received an average rating of “Hold” from the eighteen analysts that are currently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and nine have given a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $173.1875.
A number of research firms have recently commented on ICLR. TD Cowen lifted their target price on Icon from $164.00 to $197.00 and gave the stock a “buy” rating in a research note on Thursday, June 25th. Bank of America increased their price target on shares of Icon from $125.00 to $150.00 and gave the company an “underperform” rating in a research report on Thursday, June 25th. Weiss Ratings downgraded shares of Icon from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, May 29th. Truist Financial upgraded shares of Icon from a “hold” rating to a “buy” rating and boosted their target price for the company from $159.00 to $207.00 in a research note on Tuesday, June 30th. Finally, Barclays increased their target price on shares of Icon from $160.00 to $175.00 and gave the company an “equal weight” rating in a research report on Thursday, June 25th.
View Our Latest Stock Analysis on ICLR
Icon Price Performance
Icon (NASDAQ:ICLR – Get Free Report) last issued its quarterly earnings results on Tuesday, June 23rd. The medical research company reported $2.50 EPS for the quarter, beating analysts’ consensus estimates of $2.43 by $0.07. Icon had a return on equity of 8.73% and a net margin of 5.35%.The company had revenue of $2.03 billion during the quarter, compared to the consensus estimate of $1.98 billion. During the same period last year, the business posted $3.43 earnings per share. Icon’s revenue was up 2.5% on a year-over-year basis. On average, equities analysts anticipate that Icon will post 9.43 EPS for the current year.
Institutional Trading of Icon
A number of large investors have recently bought and sold shares of the company. Sanctuary Advisors LLC lifted its position in shares of Icon by 1.1% during the 4th quarter. Sanctuary Advisors LLC now owns 4,932 shares of the medical research company’s stock valued at $899,000 after buying an additional 56 shares during the last quarter. Geneos Wealth Management Inc. increased its holdings in Icon by 11.5% in the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after acquiring an additional 56 shares during the last quarter. GAMMA Investing LLC increased its holdings in Icon by 21.4% in the 2nd quarter. GAMMA Investing LLC now owns 391 shares of the medical research company’s stock worth $68,000 after acquiring an additional 69 shares during the last quarter. New Wave Wealth Advisors LLC raised its stake in Icon by 5.1% in the 4th quarter. New Wave Wealth Advisors LLC now owns 1,479 shares of the medical research company’s stock valued at $270,000 after acquiring an additional 72 shares during the period. Finally, Signaturefd LLC raised its stake in Icon by 12.6% in the 4th quarter. Signaturefd LLC now owns 643 shares of the medical research company’s stock valued at $117,000 after acquiring an additional 72 shares during the period. 95.61% of the stock is owned by hedge funds and other institutional investors.
Icon Company Profile
Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.
Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.
Featured Articles
- Five stocks we like better than Icon
- 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.
